Enterprise Value

81.65M

Cash

200M

Avg Qtr Burn

-4.681M

Short % of Float

3.54%

Insider Ownership

36.02%

Institutional Own.

11.48%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Natrunix Details
Rheumatoid arthritis, Autoimmune disease

Phase 2

Data readout

Natrunix (XB2001) Details
Cancer, Pancreatic cancer

Phase 1/2

Data readout

Hutrukin Details
Brain disease, Ischemic stroke

Phase 1

Data readout

Phase 1

Update

Bermekimab Details
Skin disease/disorder, Hidradenitis suppurativa

Failed

Discontinued

Bermekimab Details
Skin disease/disorder

Failed

Discontinued

514G3 Details
Bacterial infection, Methicillin-resistant staphylococcus aureus

Failed

Discontinued